What happened
The FDA's TEA (Time and Extent Application) process for modern UV filters has moved forward on several candidates this spring. Bemotrizinol (Tinosorb S) is now closest to approval, with bisoctrizole (Tinosorb M) and others trailing behind. None are approved yet, but stakeholders close to the process say a 2026–2027 decision is realistic.
Why it matters
- Bemotrizinol is a broad-spectrum UV filter with photostability that older US filters can't match.
- For melasma- and pigmentation-prone consumers, broader UVA-1 coverage means meaningful real-world results.
- Approval would let US brands compete texturally with European and Korean sunscreens that already dominate sensitive-skin shelves.
- Mineral-only loyalists won't be affected, but the chemical-mineral hybrid market would expand.
What to watch next
- Whether the FDA standardizes its UVA protection labeling (current "Broad Spectrum" is binary and uninformative).
- Reformulations by L'Oréal, Beiersdorf, and other multinationals that already use bemotrizinol abroad.
- Pricing — expect a 1–2 year premium on early bemotrizinol-containing US SPFs.
- Whether existing US users keep buying imports anyway.